€41.28
0.94% yesterday
Xetra, Jul 14, 05:35 pm CET
ISIN
NL0000240000
Symbol
QIA
Sector

Qiagen Target price 2025 - Analyst rating & recommendation

Qiagen Classifications & Recommendation:

Buy
58%
Hold
42%

Qiagen Price Target

Target Price €42.98
Price €41.28
Potential 4.14%
Number of Estimates 18
18 Analysts have issued a price target Qiagen 2026 . The average Qiagen target price is €42.98. This is 4.14% higher than the current stock price. The highest price target is €49.49 19.91% , the lowest is €38.95 5.63% .
A rating was issued by 24 analysts: 14 Analysts recommend Qiagen to buy, 10 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Qiagen stock has an average upside potential 2026 of 4.14% . Most analysts recommend the Qiagen stock at Purchase.

Sales and Margin forecast 2025, 2026 to 2030


Dec '24 2025
Estimates
Revenue Billion € 1.70 1.80
0.66% 6.36%
EBITDA Margin 25.51% 37.73%
9.92% 47.93%
Net Margin 4.23% 24.60%
75.67% 482.19%

27 Analysts have issued a sales forecast Qiagen 2025 . The average Qiagen sales estimate is €1.8b . This is 6.36% higher than the revenue of the last 12 months(TTM). The highest sales forecast is €1.9b 11.28% , the lowest is €1.7b 0.63% .

This results in the following potential growth metrics:

Revenue Estimates

2024 €1.7b 0.66%
2025 €1.8b 6.36%
2026 €1.9b 5.70%
2027 €2.0b 6.79%
2028 €2.3b 12.76%
2029 €2.5b 9.82%
2030 €2.9b 14.08%

24 Analysts have issued an Qiagen EBITDA forecast 2025. The average Qiagen EBITDA estimate is €679m . This is 57.34% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is €773m 78.59% , the lowest is €586m 35.56% .

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 €433m 10.64%
2025 €679m 57.34%
2026 €732m 7.74%
2027 €795m 8.69%
2028 €852m 7.14%
2029 €910m 6.83%

EBITDA Margin

2024 25.51% 9.92%
2025 37.73% 47.93%
2026 38.46% 1.93%
2027 39.14% 1.77%
2028 37.19% 4.98%
2029 36.18% 2.72%

27 Qiagen Analysts have issued a net profit forecast 2025. The average Qiagen net profit estimate is €443m . This is 519.30% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is €461m 542.78% , the lowest is €422m 489.06% .

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 €71.7m 75.51%
2025 €443m 519.30%
2026 €481m 8.61%
2027 €528m 9.69%
2028 €592m 12.17%
2029 €631m 6.55%

Net Margin

2024 4.23% 75.67%
2025 24.60% 482.19%
2026 25.28% 2.76%
2027 25.97% 2.73%
2028 25.83% 0.54%
2029 25.06% 2.98%

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2030


Dec '24 2025
Estimates
Earnings Per Share 0.33 2.05
74.81% 521.21%
P/E 19.95
EV/Sales 5.07

27 Analysts have issued a Qiagen forecast for earnings per share. The average Qiagen EPS is €2.05 . This is 561.29% higher than earnings per share in the financial year 2024. The highest EPS forecast is €2.13 587.10% , the lowest is €1.95 529.03% .

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 €0.33 74.81%
2025 €2.05 521.21%
2026 €2.23 8.78%
2027 €2.44 9.42%
2028 €2.74 12.30%
2029 €2.92 6.57%

P/E ratio

Current 131.90 1.95%
2025 19.95 84.88%
2026 18.37 7.92%
2027 16.75 8.82%
2028 14.93 10.87%
2029 14.02 6.10%

Based on analysts' sales estimates for 2025, the Qiagen stock is valued at an EV/Sales of 5.07 and an P/S ratio of 4.95 .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 5.39 2.86%
2025 5.07 5.99%
2026 4.79 5.40%
2027 4.49 6.36%
2028 3.98 11.31%
2029 3.63 8.94%
2030 3.18 12.34%

P/S ratio

Current 5.27 5.98%
2025 4.95 5.98%
2026 4.69 5.40%
2027 4.39 6.36%
2028 3.89 11.32%
2029 3.54 8.94%
2030 3.11 12.34%

Current Qiagen Upgrades & Downgrades

Analyst Rating Action Date
B of A Securities
Buy
Buy
Unchanged Jun 26 2025
Barclays
Overweight
Initiated Jun 24 2025
Baird
Neutral
Neutral
Unchanged Apr 21 2025
Redburn Atlantic
Buy
Neutral
Downgrade Apr 04 2025
Baird
Outperform
Neutral
Downgrade Feb 19 2025
UBS
Neutral
Neutral
Unchanged Feb 07 2025
Morgan Stanley
Overweight
Equal-Weight
Downgrade Jan 06 2025
Analyst Rating Date
Unchanged
B of A Securities:
Buy
Buy
Jun 26 2025
Initiated
Barclays:
Overweight
Jun 24 2025
Unchanged
Baird:
Neutral
Neutral
Apr 21 2025
Downgrade
Redburn Atlantic:
Buy
Neutral
Apr 04 2025
Downgrade
Baird:
Outperform
Neutral
Feb 19 2025
Unchanged
UBS:
Neutral
Neutral
Feb 07 2025
Downgrade
Morgan Stanley:
Overweight
Equal-Weight
Jan 06 2025

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today